|
2024 Journal Article Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy responseSadeghirad, Habib, Monkman, James, Tan, Chin Wee, Liu, Ning, Yunis, Joseph, Donovan, Meg L., Moradi, Afshin, Jhaveri, Niyati, Perry, Chris, Adams, Mark N., O’Byrne, Ken, Warkiani, Majid E., Ladwa, Rahul, Hughes, Brett G.M. and Kulasinghe, Arutha (2024). Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy response. Journal of Translational Medicine, 22 (1) 677, 677. doi: 10.1186/s12967-024-05409-y |
|
2024 Journal Article A phase Ib study to assess the safety of the human papillomavirus DNA vaccine (AMV002) in combination with durvalumab for HPV-associated oropharyngeal squamous cell carcinomaLadwa, Rahul, Chandra, Janin, Woo, Wai-Ping, Finlayson, Neil, Liu, Howard, McGrath, Margaret, See, Adrienne, Hughes, Brett G., Cooper, Caroline L., Jackson, Jim E., Dzienis, Marcin, Xu, Yan, Panizza, Benedict, Frazer, Ian and Porceddu, Sandro V. (2024). A phase Ib study to assess the safety of the human papillomavirus DNA vaccine (AMV002) in combination with durvalumab for HPV-associated oropharyngeal squamous cell carcinoma. Frontiers in Oncology, 14 1419258, 1-8. doi: 10.3389/fonc.2024.1419258 |
|
2024 Journal Article Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label studyCho, Byoung Chul, Braña, Irene, Cirauqui, Beatriz, Aksoy, Sercan, Couture, Felix, Hong, Ruey-Long, Miller, Wilson H., Chaves-Conde, Manuel, Teixeira, Margarida, Leopold, Lance, Munteanu, Mihaela, Ge, Joy Yang, Swaby, Ramona F. and Hughes, Brett G. M. (2024). Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study. BMC Cancer, 23 (Suppl 1) 1254, 1-12. doi: 10.1186/s12885-023-11316-0 |
|
2024 Journal Article Avelumab in combination with lorlatinib or crizotinib in patients with previously treated advanced NSCLC: phase 1b/2 results from the JAVELIN lung 101 trialSolomon, Benjamin J., Dagogo-Jack, Ibiayi, Lee, Se-Hoon, Boyer, Michael J., Ramalingam, Suresh S., Carcereny, Enric, Felip, Enriqueta, Han, Ji-Youn, Hida, Toyoaki, Hughes, Brett G.M., Kim, Sang-We, Nishio, Makoto, Seto, Takashi, Okamoto, Tatsuro, Zhang, Xiaoxi, Martini, Jean-Francois, Wang, Erjian, De Beukelaer, Steven and Bauer, Todd M. (2024). Avelumab in combination with lorlatinib or crizotinib in patients with previously treated advanced NSCLC: phase 1b/2 results from the JAVELIN lung 101 trial. JTO Clinical and Research Reports, 5 (7) 100685. doi: 10.1016/j.jtocrr.2024.100685 |
|
2024 Conference Publication A phase 2 study of de-escalation in resectable, locally advanced cutaneous squamous cell carcinoma (cSCC) with the use of neoadjuvant pembrolizumab: De-SquamateLadwa, Rahul, Lee, Jenny H.J., Porceddu, Sandro V., McGrath, Margaret Louise, Cooper, Caroline, Liu, Howard, Gupta, Ruta, Cuscaden, Claire, Nottage, Michelle K., Clark, Jonathan, Le, Dieu, Pauley, Marketa, Gonzalez-Cruz, Jazmina, Frazer, Ian, Hughes, Brett Gordon Maxwell and Panizza, Benedict J. (2024). A phase 2 study of de-escalation in resectable, locally advanced cutaneous squamous cell carcinoma (cSCC) with the use of neoadjuvant pembrolizumab: De-Squamate. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.9514 |
|
2024 Journal Article Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancerFelip, Enriqueta, Metro, Giulio, Tan, Daniel S.W., Wolf, Juergen, Mark, Michael, Boyer, Michael, Hughes, Brett G. M., Bearz, Alessandra, Moro-Sibilot, Denis, Le, Xiuning, Puente, Javier, Massuti, Bartomeu, Tiedt, Ralph, Wang, Yingying, Xu, Chao, Mardjuadi, Feby I. and Cobo, Manuel (2024). Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancer. Lung Cancer, 192 107820, 107820. doi: 10.1016/j.lungcan.2024.107820 |
|
2024 Journal Article Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trialMachiels, Jean-Pascal, Tao, Yungan, Licitra, Lisa, Burtness, Barbara, Tahara, Makoto, Rischin, Danny, Alves, Gustavo, Lima, Iane Pinto Figueiredo, Hughes, Brett G M, Pointreau, Yoann, Aksoy, Sercan, Laban, Simon, Greil, Richard, Burian, Martin, Hetnał, Marcin, Delord, Jean-Pierre, Mesía, Ricard, Taberna, Miren, Waldron, John N, Simon, Christian, Grégoire, Vincent, Harrington, Kevin J, Swaby, Ramona F, Zhang, Yayan, Gumuscu, Burak, Bidadi, Behzad, Siu, Lillian L, Hughes, Brett GM, Gao, Bo ... Obara, Grzegorz S (2024). Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. The Lancet Oncology, 25 (5), 572-587. doi: 10.1016/S1470-2045(24)00100-1 |
|
2024 Journal Article Human papillomavirus associated oropharyngeal cancer now the most common mucosal head and neck cancer in QueenslandPorceddu, Sandro, Negrello, Theresa, Rawson, Neal, Dunn, Nathan, Batstone, Martin, Collins, Michael, Dowthwaite, Sam, Hughes, Brett G. M., Kenny, Liz, Ladwa, Rahul, Panizza, Ben and Cossio, Danica (2024). Human papillomavirus associated oropharyngeal cancer now the most common mucosal head and neck cancer in Queensland. Journal of Medical Imaging and Radiation Oncology, 68 (4), 472-480. doi: 10.1111/1754-9485.13643 |
|
2024 Conference Publication Spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma revealed immune cell type infiltration into the TME as a predictor of immunotherapy responseSadeghirad, Habib, Tan, Chin Wee, Liu, Ning, Monkman, James, Cooper, Caroline, O’Byrne, Ken, Davis, Melissa, Hughes, Brett and Kulasinghe, Arutha (2024). Spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma revealed immune cell type infiltration into the TME as a predictor of immunotherapy response. American Association for Cancer Research Annual Meeting 2024, San Diego, CA United States, 5-10 April 2024. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2024-1154 |
|
2024 Conference Publication Defining PD-1/PD-L1 receptor-ligand interactions in the head and neck cancer tumor microenvironment identifies unique ‘immune cell rivers’ of cellular interactionsSadeghirad, Habib, Naei, Vahid Yaghoubi, Monkman, James, Basu, Subham, Wicher, Agata, Ladwa, Rahul, Hughes, Brett G.M. and Kulasinghe, Arutha (2024). Defining PD-1/PD-L1 receptor-ligand interactions in the head and neck cancer tumor microenvironment identifies unique ‘immune cell rivers’ of cellular interactions. American Association for Cancer Research Annual Meeting 2024, San Diego, CA United States, 5-10 April 2024. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2024-5188 |
|
2024 Journal Article High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinomaRischin, Danny, Hughes, Brett G. M., Basset-Séguin, Nicole, Schadendorf, Dirk, Bowyer, Samantha, Trabelsi Messai, Sabiha, Meier, Friedegund, Eigentler, Thomas K, Casado Echarren, Victoria, Stein, Brian, Beylot-Barry, Marie, Dalac, Sophie, Dréno, Brigitte, Migden, Michael R, Hauschild, Axel, Schmults, Chrysalyne D, Lim, Annette M, Yoo, Suk-Young, Paccaly, Anne J, Papachristos, Apostolos, Nguyen, Jenny-Hoa, Okoye, Emmanuel, Seebach, Frank, Booth, Jocelyn, Lowy, Israel, Fury, Matthew G and Guminski, Alexander (2024). High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma. Journal for ImmunoTherapy of Cancer, 12 (3) e008325, 1-8. doi: 10.1136/jitc-2023-008325 |
|
2024 Journal Article Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programmeAlexander, Marliese, Rogers, Jennifer, Parakh, Sagun, Mitchell, Paul, Clay, Timothy D., Kao, Steven, Hughes, Brett G. M., Itchins, Malinda, Kong, Benjamin Y., Pavlakis, Nick, Solomon, Benjamin J. and John, Thomas (2024). Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme. Internal Medicine Journal, 54 (7), 1087-1096. doi: 10.1111/imj.16348 |
|
2024 Journal Article Nutrition outcomes and treatment toxicities in patients with head and neck cancer receiving helical intensity-modulated radiotherapyBlake, Claire, Lai, Rainbow, Brown, Teresa, Pelecanos, Anita, Moroney, Laura, Helios, Jennifer, Smith, David, Hughes, Brett G. M., Kenny, Lizbeth, Chua, Benjamin and Bauer, Judith (2024). Nutrition outcomes and treatment toxicities in patients with head and neck cancer receiving helical intensity-modulated radiotherapy. Journal of Human Nutrition and Dietetics, 37 (1), 182-192. doi: 10.1111/jhn.13243 |
|
2024 Journal Article Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort studyMcLean, Luke S, Lim, Annette M, Bressel, Mathias, Lee, Jenny, Ladwa, Rahul, Guminski, Alexander D, Hughes, Brett, Bowyer, Samantha, Briscoe, Karen, Harris, Samuel, Kukard, Craig, Zielinski, Rob, Alamgeer, Muhammad, Carlino, Matteo, Mo, Jeremy, Park, John J, Khattak, Muhammad A, Day, Fiona and Rischin, Danny (2024). Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study. Medical Journal of Australia, 220 (2), 80-90. doi: 10.5694/mja2.52199 |
|
2023 Journal Article Health-related quality of life with pembrolizumab in patients with locally advanced or recurrent or metastatic cutaneous squamous cell carcinoma: KEYNOTE-629Bratland, Åse, Munoz-Couselo, Eva, Mortier, Laurent, Roshdy, Osama, González, Rene, Schachter, Jacob, Arance, Ana M., Grange, Florent, Meyer, Nicolas, Joshi, Abhishek Jagdish, Billan, Salem, Hughes, Brett G. M., Grob, Jean-Jacques, Ramakrishnan, Karthik, Ge, Joy, Gumuscu, Burak, Swaby, Ramona F. and Gutzmer, Ralf (2023). Health-related quality of life with pembrolizumab in patients with locally advanced or recurrent or metastatic cutaneous squamous cell carcinoma: KEYNOTE-629. Dermatology and Therapy, 13 (12), 3165-3180. doi: 10.1007/s13555-023-01059-y |
|
2023 Journal Article A tailored approach to horizon scanning for cancer medicinesSoon, Jennifer A., To, Yat Hang, Alexander, Marliese, Trapani, Karen, Ascierto, Paolo A., Athan, Sophy, Brown, Michael P., Burge, Matthew, Haydon, Andrew, Hughes, Brett, Itchins, Malinda, John, Thomas, Kao, Steven, Koopman, Miriam, Li, Bob T., Long, Georgina V., Loree, Jonathan M., Markman, Ben, Meniawy, Tarek M., Menzies, Alexander M., Nott, Louise, Pavlakis, Nick, Petrella, Teresa M., Popat, Sanjay, Tie, Jeanne, Xu, Wen, Yip, Desmond, Zalcberg, John, Solomon, Benjamin J. ... IJzerman, Maarten (2023). A tailored approach to horizon scanning for cancer medicines. Journal of Cancer Policy, 38 100441, 1-8. doi: 10.1016/j.jcpo.2023.100441 |
|
2023 Journal Article Development and validation of txSim: A model of advanced lung cancer treatment in AustraliaNgo, Preston, Karikios, Deme, Goldsbury, David, Wade, Stephen, Lwin, Zarnie, Hughes, Brett G. M., Fong, Kwun M., Canfell, Karen and Weber, Marianne (2023). Development and validation of txSim: A model of advanced lung cancer treatment in Australia. PharmacoEconomics, 41 (11), 1525-1537. doi: 10.1007/s40273-023-01291-6 |
|
2023 Journal Article Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 studyGross, Neil D., Miller, David M., Khushalani, Nikhil I., Divi, Vasu, Ruiz, Emily S., Lipson, Evan J., Meier, Friedegund, Su, Yungpo Bernard, Swiecicki, Paul L., Atlas, Jennifer, Geiger, Jessica L., Hauschild, Axel, Choe, Jennifer H., Hughes, Brett G. M., Schadendorf, Dirk, Patel, Vishal A., Homsi, Jade, Taube, Janis M., Lim, Annette M., Ferrarotto, Renata, Yoo, Suk-Young, Mathias, Melissa, Han, Hyunsil, Seebach, Frank, Lowy, Israel, Fury, Matthew G. and Rischin, Danny (2023). Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study. The Lancet Oncology, 24 (11), 1196-1205. doi: 10.1016/S1470-2045(23)00459-X |
|
2023 Journal Article Mapping the spatial proteome of head and neck tumors: key immune mediators and metabolic determinants in the tumor microenvironmentJhaveri, Niyati, Ben Cheikh, Bassem, Nikulina, Nadezhda, Ma, Ning, Klymyshyn, Dmytro, DeRosa, James, Mihani, Ritu, Pratapa, Aditya, Kassim, Yasmin, Bommakanti, Sidharth, Shang, Olive, Berry, Shannon, Ihley, Nicholas, McLane, Michael, He, Yan, Zheng, Yi, Monkman, James, Cooper, Caroline, O'Byrne, Ken, Anand, Bhaskar, Prater, Michael, Basu, Subham, Hughes, Brett G. M., Kulasinghe, Arutha and Braubach, Oliver (2023). Mapping the spatial proteome of head and neck tumors: key immune mediators and metabolic determinants in the tumor microenvironment. GEN Biotechnology, 2 (5), 418-434. doi: 10.1089/genbio.2023.0029 |
|
2023 Conference Publication Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT)Dingemans, Anne-Marie C., Syrigos, Konstantinos, Livi, Lorenzo, Paulus, Astrid, Kim, Sang-We, Chen, Yuanbin, Felip, Enriqueta, Griesinger, Frank, Ohashi, Kadoaki, Zalcman, Gerard, Hughes, Brett Gordon Maxwell, Sorensen, Jens Benn, Blais, Normand, Ferreira, Carlos G. M., Lindsay, Colin R, Dziadziuszko, Rafal, Ward, Patrick J., Obiozor, Cynthia Chinedu, Wang, Yang and Peters, Solange (2023). Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT). 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.17_suppl.lba9016 |
